ATR/CHK1 inhibitors and cancer therapy

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Cell cycle checkpoint proteins ATR and CHK1 are crucial for preventing mitosis in cells with DNA damage or replication stress.
• These proteins are particularly important in cancer cells with defective G1 checkpoints (e.g., due to p53 mutations) and suppress replication stress caused by oncogene activation.
• ATR/CHK1 functions make them attractive therapeutic targets for cancer treatment.

Purpose of the Study:

• To review the development status of ATR and CHK1 inhibitors.
• To discuss mechanisms of ATR/CHK1 inhibition-induced cell killing, with or without DNA damaging agents.
• To explore synthetic lethality interactions between ATR/CHK1 inhibition and other DNA damage response pathways.

Main Methods:

• Literature review of preclinical and clinical studies on ATR and CHK1 inhibitors.
• Analysis of proposed mechanisms for ATR/CHK1 inhibitor efficacy.
• Examination of synthetic lethality interactions in DNA damage response (DDR) pathways.

Main Results:

• ATR and CHK1 inhibitors are in active preclinical and clinical development, used alone or with radiation therapy (RT) and chemotherapy.
• ATR/CHK1 inhibition can induce cancer cell killing through various mechanisms, potentially enhanced by RT or chemotherapy.
• Combinations of ATR/CHK1 inhibition with defects in other DDR pathways may lead to synthetic lethality, offering novel therapeutic strategies.

Conclusions:

• ATR and CHK1 inhibitors represent a promising class of targeted cancer therapeutics.
• Understanding the mechanisms of action and synthetic lethality is key to optimizing their clinical application.
• Further research into ATR/CHK1 inhibition combinations holds significant potential for improving cancer treatment outcomes.